Immuno-Oncology At US FDA: Where Are The PD-1/L1 Inhibitor Applications?
Executive Summary
Infographic guide to the almost 40 indications for burgeoning PD-1/L1 checkpoint inhibitor class either approved or under review, from the Pink Sheet's FDA Performance Tracker.
You may also be interested in...
US FDA’s Information First Policy: PD-1 Bladder Cancer Alert Aligns With Complementary Diagnostics Perspective
Tecentriq and Keytruda's apparently lower efficacy in low PD-1/L1 patients in ongoing first-line trials prompts communication instead of restriction, underscoring FDA's emerging approach to precision medicine labeling.
Collaboration Makes The (Real) World Go Round: Global Efforts Strive To Anchor RWE With Real-World Data Standards And Practices
Can the decentralized global healthcare ecosystem to turn real-world evidence from a buzzword to a useful approach to fit-for-purpose evidence generation?
Piloting Real-World Evidence: US FDA RWE Demonstration Projects
Agency offers three informal ‘buckets’ organized around data, study design and tools.